Ironwood Pharmaceuticals

IRWD · Nasdaq · United States

Share price · IRWD

$4.78+0.47 (+10.90%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.2M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IRWD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+8.9%
  2. 4 Nov 2026+7.7%

    Nothing announced by IRWD that day or the session before.

  3. 31 Jul 2026+13.4%

    Nothing announced by IRWD that day or the session before.

  4. 13 May 2026-10.0%
  5. 7 May 2026-13.7%
  6. 1 Apr 2026+11.1%

    Nothing announced by IRWD that day or the session before.

  7. 2 Jan 2026+26.7%
  8. 26 Nov 2025+23.3%

Share of unusual movement by asset

For each asset, the share of IRWD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
apraglutide
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—6%
Other company news (earnings, financing, releases naming no asset)—34%
Sessions with no dated event—60%

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
linaclotide(Linzess)
Approved
Guanylate cyclase-C (GC-C)Peptide
Irritable Bowel Syndrome
Irritable Bowel Syndrome with Constipation
Phase 3
GLP-2 receptorPeptide
Short Bowel Syndrome

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (21)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$133M$28M$86M—$67M operating cash flowreport ↗
View 20 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$113M$22M$79M—$58M operating cash flowreport ↗
2026-Q1$107M$22M$220M—$5.1M operating cash flowreport ↗
2025-Q4$48M—$215M$2.3M$75M operating cash flowreport ↗
2025-Q3$122M$22M$140M—$48M operating cash flowreport ↗
2025-Q2$85M$23M$93M—-$15M operating cash flowreport ↗
2025-Q1$41M$27M$108M$37M$20M operating cash flowreport ↗
2024-Q4$91M—$89M—$15M operating cash flowreport ↗
2024-Q3$92M$30M$88M—$9.9M operating cash flowreport ↗
2024-Q2$94M$30M$106M$0.9M$33M operating cash flowreport ↗
2024-Q1$75M$26M$122M$4.2M$45M operating cash flowreport ↗
2023-Q4$118M—$92M$1.1M$36M operating cash flowreport ↗
2023-Q3$114M$33M$111M—$32M operating cash flowreport ↗
2023-Q2$107M$35M$177M$1.1B$35M operating cash flowreport ↗
2023-Q1$104M$13M$742M—$80M operating cash flowreport ↗
2022-Q4$107M—$658M—$79M operating cash flowreport ↗
2022-Q3$109M$12M$576M—$69M operating cash flowreport ↗
2022-Q2$97M$11M$506M—$61M operating cash flowreport ↗
2022-Q1$98M$11M$595M—$64M operating cash flowreport ↗
2021-Q4$117M—$622M—$65M operating cash flowreport ↗
2021-Q3$104M$11M$576M—$75M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$296M$95M$215M—$127M operating cash flowreport ↗

Ironwood reported full-year 2025 revenue of $296.15M, down 15.7% YoY, with R&D spend of $95.14M, down 14.6% YoY. The company ended the period with $215.46M in cash and cash equivalents and recorded GAAP net income of $24.02M, or $0.15 per share basic and diluted.

The company reiterated 2026 guidance for LINZESS U.S. net sales of $1.125B to $1.175B, total revenues of $450M to $475M, and adjusted EBITDA above $300M. Key elements of the confirmatory Phase 3 STARS-2 trial design for apraglutide in short bowel syndrome with intestinal failure were finalized, with site initiations expected in Q2 2026. In November 2025, the FDA approved LINZESS for irritable bowel syndrome with constipation in patients aged 7 years and older, and Ironwood settled litigation with Ferring in December 2025, agreeing to pay $12.5M, of which $7.5M was paid and $5.0M is due by December 31, 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$351M$111M$89M—$104M operating cash flowreport ↗
2023-FY$443M$116M$92M$251M$183M operating cash flowreport ↗
2022-FY$411M$44M$658M—$274M operating cash flowreport ↗
2021-FY$414M$70M$622M—$262M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 18 sales ($22.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Gaskins Tammi L · Chief Commercial OfficerOpen-market sale5,919$4.81$28KForm 4
2026-09-15DENNER ALEXANDER J · directorAward / grant3,694——Form 4
2026-07-20Silber Jeffrey · SVP, CMO, Head-Res&DrugAward / grant137,036——Form 4
2026-07-07Silver Ronald · PFO & PAOOpen-market sale127,890$4.52$578KForm 4
2026-06-16Moukheibir Catherine · directorAward / grant63,481——Form 4
2026-06-16McHugh Julie · directorAward / grant63,481——Form 4
2026-06-16Duane Jon R · directorAward / grant63,481——Form 4
2026-06-16Currie Mark G · directorAward / grant63,481——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 223 reporting institutions held 160.2M shares ($534.6M, 96.7% of shares outstanding).

#InstitutionSharesValue
1ARMISTICE CAPITAL, LLC15,028,000$52.7M
2BlackRock, Inc.13,362,930$46.9M
3Sarissa Capital Management LP9,188,635$32.3M
4BANK OF AMERICA CORP /DE/8,682,907$30.5M
5RENAISSANCE TECHNOLOGIES LLC8,061,073$28.3M
6AQR CAPITAL MANAGEMENT LLC7,535,080$26.4M
7STATE STREET CORP7,456,944$26.2M
8VANGUARD PORTFOLIO MANAGEMENT LLC6,682,037$23.5M
9VANGUARD CAPITAL MANAGEMENT LLC6,097,454$21.4M
10TWO SIGMA INVESTMENTS, LP5,848,276$20.5M
11CHARLES SCHWAB INVESTMENT MANAGEMENT INC4,737,857$16.6M
12GEODE CAPITAL MANAGEMENT, LLC4,543,522$16.0M
13MARSHALL WACE, LLP4,525,064$15.9M
14JACOBS LEVY EQUITY MANAGEMENT, INC3,632,477$12.7M
15ARROWSTREET CAPITAL, LIMITED PARTNERSHIP3,397,242$11.9M